VI
Vivo Bio Tech Ltd (VIVOBIOT)
₹16.01
Mkt cap
₹36 Cr
P/E ratio
—
P/B
0.38
Div yield
0.00%
ROE
−2.24%
ROCE
7.74%
EPS (TTM)
—
Book value
₹43
52W range
12–21
Sector
Healthcare
Price history
Previous close
Incorporated in 1987, Vivo Bio Tech Ltd is engaged in service of CRO offering Drug Development & Discovery Services to Pharmaceutical & Biotech Companies [1]
NSE VIVOBIOTBSE 511509
Health check
Cautious
ProfitabilityWeak
GrowthModerate
TechnicalsNeutral
52-week range
−23.54% from high₹16
₹12+33.42% from low₹21
Current
₹16.01
Prev close
₹14.32
Day
+11.80%
Price performance
1D
+9.64%
1W
−4.62%
1M
+6.80%
3M
−18.61%
6M
—
1Y
—
YTD
−18.65%
Financials
Revenue, profit & margin
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 9.26 | 12.85 | 11.76 | 10.13 | 12.04 | 12.21 | 12.29 | 12.51 | 13.11 | 13.51 | 14.20 | 14.28 | 17.19 | |
| YoY Sales growth | -26.91% | -5.10% | -20.33% | -12.52% | +30.02% | -4.98% | +4.51% | +23.49% | +8.89% | +10.65% | +15.54% | +14.15% | +31.12% | |
| Expenses | 4.40 | 6.48 | 6.39 | 5.77 | 6.45 | 6.67 | 7.27 | 7.03 | 7.69 | 8.02 | 9.75 | 9.23 | 11.10 | |
| Operating Profit | 4.86 | 6.37 | 5.37 | 4.36 | 5.59 | 5.54 | 5.02 | 5.48 | 5.42 | 5.49 | 4.45 | 5.05 | 6.09 | |
| OPM % | 52.48% | 49.57% | 45.66% | 43.04% | 46.43% | 45.37% | 40.85% | 43.80% | 41.34% | 40.64% | 31.34% | 35.36% | 35.43% | |
| Other Income | 0.00 | 0.03 | 0.01 | 0.01 | 4.63 | 0.01 | 0.15 | 0.14 | 0.13 | 0.14 | 0.03 | 0.06 | 1.55 | |
| Interest | 2.09 | 2.22 | 1.52 | 1.92 | 2.06 | 1.84 | 1.68 | 1.50 | 1.47 | 1.40 | 1.48 | 1.24 | 2.02 | |
| Depreciation | 2.30 | 2.28 | 2.43 | 2.23 | 2.29 | 2.25 | 2.25 | 2.64 | 2.57 | 2.66 | 2.75 | 3.53 | 3.75 | |
| Profit before tax | 0.47 | 1.90 | 1.43 | 0.22 | 5.87 | 1.46 | 1.24 | 1.48 | 1.51 | 1.57 | 0.25 | 0.34 | 1.87 | |
| Tax % | 29.79% | 31.05% | 48.95% | 27.27% | 10.73% | 43.84% | 14.52% | 9.46% | 42.38% | 20.38% | 2,164.00% | 44.12% | 41.18% | |
| Net Profit | 0.33 | 1.32 | 0.74 | 0.17 | 5.23 | 0.82 | 1.06 | 1.34 | 0.87 | 1.25 | -5.16 | 0.19 | 1.10 | |
| EPS in Rs | 0.22 | 0.89 | 0.50 | 0.11 | 3.51 | 0.51 | 0.62 | 0.67 | 0.39 | 0.57 | -2.33 | 0.09 | 0.50 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
No reaction history yet.
No quarterly filings ingested yet.
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202622.51%Promoter
Promoters22.51%8.11
Public77.50%8.11
Ownership trend
Peers
7 companies| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Anthem Bioscienc | ₹951.05 | 84.88 | 53,589 | 0.21% | 211 | +21.93% | 594 | +8.00% | 30.37% |
| Advanced Enzyme | ₹290.45 | 19.57 | 3,182 | 1.84% | 51 | +11.49% | 215 | +16.25% | 13.96% |
| Ennature Bio Pharma | ₹167.65 | 49.29 | 375 | 0.00% | 5 | +482.03% | 78 | +44.92% | — |
| CCME Global | ₹35.19 | — | 159 | 0.00% | 0 | −266.67% | 0 | — | −2.92% |
| Vivo Bio Tech | ₹16.01 | — | 36 | 0.00% | 1 | +26.44% | 17 | +31.12% | 7.74% |
| Shree Ganesh Bio | ₹0.44 | — | 18 | 0.00% | 0 | −900.00% | 0 | −79.22% | 1.31% |
| Genomic Valley | ₹44.75 | — | 14 | 0.00% | 0 | — | 0 | −100.00% | 1.02% |
| Median: 4 Co. | ₹229.05 | 49.29 | 1,778 | 0.10% | 28 | +16.71% | 146 | +16.25% | 13.96% |
Filings
Annual reports15
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Newspaper Publication 13 Nov - Newspaper Publication of financial results for the second quarter & half year ended September 30, 2026.Report On Re-Lodgement Of Transfer Requests Of Physical Shares 12 Nov - Reported nil re-lodgement transfer requests for physical shares in October 2026.Unaudited Financial Results For The Qtr And Half Year Ended 30Th September 2026 11 Nov - Board approved unaudited standalone and consolidated Q2 FY2026 results on November 11, 2026.Board Meeting Outcome for Outcome Of The Board Meeting 11 Nov - Board approved unaudited standalone and consolidated Q2 FY2026 results on November 11, 2026.Board Meeting Intimation for Board Meeting Intimation For, To Consider And Approve The Financial Results For The Quarter And Half Year Ended On 30Th September, 2026 2 Nov - Board meets on November 11, 2026 to approve Q2 FY2027 unaudited results; trading window closed until 48 hours after results.

